GlaxoSmithKline has opted for a demerger to execute the much-anticipated separation of its Consumer Healthcare business from its biopharma operation as this route best maximizes shareholder value, according to CEO Emma Walmsley.
GSK To Spin Off And List Consumer Healthcare Business In 2022
GSK will demerge its Consumer Healthcare business in mid-2022 and list the new company on the London Stock Exchange. The move will “create new world leader in consumer healthcare,” according to GSK, with annual sales in excess of £10bn.
